The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Association between IgA during ibrutinib therapy and infection in CLL
Andrea Visentin, MD, PhD, University of Padua, Padova, Italy, discusses the association between immunoglobulin A (IgA) during ibrutinib therapy and rates of infection in patients with chronic lymphocytic leukemia (CLL). Dr Visentin gives an overview of the rationale for this investigation and reports that IgA levels increases during ibrutinib therapy and is subsequently associated with a shorter risk to infection after the first year of ibrutinib therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Andrea Visentin, MD, PhD, has participated in consultancy work for Gilead, Italffarmaco, Janssen, and Takeda; is a member of the scientific boards of Janssen, Abbvie, CLS Behring; and has participated in speaker’s bureaus for Janssen, Abbvie, AstraZeneca.
